Forging New Pathways in Treatment

As a part of Argos’ commitment to bringing new treatments to patients quickly and efficiently, the company conducts clinical trials and sponsors investigator research, collaborating with some of the world’s leading experts in immunotherapy.

ADAPT Phase 3 Clinical Trial

The ADAPT Kidney Cancer Study is a randomized, multi-center, open-label clinical trial and is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC).

This ongoing pivotal study is expected to enroll 450 patients across approximately 140 sites, in North America, Europe and Israel. For more information about AGS-003 and the ongoing ADAPT study, visit